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Several adsorptive type devices for ulcerative colitis are used for the induction of
remission in patients with active severe disease worldwide. In 2020, the novel
apheresis device Immunopure for ulcerative colitis was launched in Japan.
Immunopure, like the polyethylene terephthalate column, uses polyarylate, a type
of polyester resin, as the adsorbent. Similar to the cellulose acetate column,
Immunopure is filled with adsorbent beads and expected to provide ease of use,
with minimal risk of column clogging. Immunopure adsorbs leukocytes and plate-
lets, especially activated platelets and platelet-leukocyte aggregates. In this article,
the capability of Immunopure is evaluated from clinical perspective based on a
clinical trial in Japan/Europe. As a result, Immunopure is comparable to other
products in clinical effectiveness and indicated for the treatment of patients with
refractory moderate ulcerative colitis, making it highly useful in clinical practice.
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1 | INTRODUCTION
Inflammatory bowel diseases, such as ulcerative colitis
(UC) and Crohn's disease, have recently been considered
major indications for therapeutic apheresis in the extra-
corporeal therapy area. In Japan, two types of apheresis
devices, polyethylene terephthalate (PET) and cellulose
acetate (CA) columns, have been approved for marketing
and reimbursed by health insurance until recently
(Table 1). In the treatment of UC, the PET type device is
indicated for the induction of remission in patients with
active severe or moderate disease, and the CA type device
for the induction of remission in patients with active
severe disease. On the other hand, the novel apheresis
device Immunopure (NIKKISO Co., Ltd. Tokyo, Japan)
(Figure 1) for UC was launched in March 2020, resulting
again in two options and a product indicated for moder-
ate cases becoming clinically available.
This article provides an overview of the features of
the new option Immunopure and its clinical results
obtained overseas and in Japan.
2 | MATERIALS AND METHODS
2.1 | Performance of materials
The adsorption performance of individual devices,
including those which are no longer available in clinical
practice, is concluded from any published literatures [1–
4] for the CA and PET columns, and the results of previ-
ous clinical trials [5] for Immunopure is shown in
Table 2. The CA column mainly removes monocytes
(about 19.5% on average) and granulocytes (about 26% on
average), which are involved in inflammation, with a low
lymphocyte adsorption/removal rate of 0% to less than
7%. In contrast, the PET column provided higher treat-
ment efficiency, having the ability to remove about 57%
of platelets on average in addition to about 79% of mono-
cytes and about 90% of granulocytes on average. How-
ever, the PET column had the disadvantage of removing
as many as about 55% of lymphocytes on average.
Immunopure is comparable to the PET column in terms
of the ability to adsorb about 46% of monocytes, about
35% of granulocytes, and about 45% of platelets on aver-
age and has a low mean lymphocyte adsorption/removal
rate of about 3%, offering an advantage similar to that of
the CA column. Ramlow et al. [5] have reported changes
in blood cell populations between the inlet and outlet of
the Immunopure adsorber in a clinical study. After the ini-
tiation of treatment, platelets in the outlet were reduced to
31%, monocytes to 30%, and granulocytes to 53%, while
lymphocytes only underwent a minor change. Waitz et al.
[6] also evaluated changes in platelet-monocyte aggregates,
platelet-T cell aggregates, and platelet-macrophage aggre-
gates by flow cytometry. Compared with healthy subjects,
patients with UC were found to have significant increases
in aggregates of activated CD42+ platelets and CD14+
TABLE 1 Commercialized/commercial device for leukocyte/granulocyte apheresis











Indications Granulocyte adsorption to induce
remission in patients with active
(only those with severe disease as
defined by severity criteria)
Leukocyte adsorption to induce
remission in patients with active
(only those with steroid refractory
severe or moderate panclotis or
left-sided colitis)
For leukocyte apheresis to induce
remission in patients with active
(only those with refractory
moderate disease)
Adsorbent Cellulose acetate beads Non-woven polyester fabric Polyarylate resin beads
Adsorbate Leukocytes (monocytes and
granulocytes)
Leukocytes and Platelets (monocytes,
granulocytes, and lymphocytes)
Activated leukocytes and platelets
(monocytes and granulocytes)
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monocytes, those of activated CD42+ platelets and CD3+
T cells, and those of activated CD42+ platelets and CD11b
+ macrophages. Of note, even after 60 min of treatment
with Immunopure, significant reductions in aggregates of
activated platelets and monocytes, those of activated plate-
lets and T cells, and those of activated platelets and macro-
phages were maintained in the outlet of the adsorber
compared with the inlet levels. The proper removal of these
activated immune-related blood components is crucial in
helping patients achieve clinical remission.
2.2 | Clinical performance
2.2.1 | Clinical trial in Germany
In a clinical trial of the Immunopure adsorber conducted
by Ramlow et al. [5], Immunopure was used in the same
manner as that applied in Japan in 2012, that is, once
weekly for 5 consecutive weeks. The study population con-
sisted of 10 patients with moderate UC (Rachilewitz Clini-
cal Activity Index: 6–10). Clinical remission was achieved
in 80% of patients, many of whom showed responses at
the end of treatment, with a further reduction in clinical
activity index (CAI) at Week 4 post-end of treatment.
2.2.2 | Prospective randomized
multicenter controlled study in Germany
In addition, Kruis et al. [7] have reported the results of a
prospective, randomized, multicenter, controlled study in
22 patients with UC with inadequate response to
5-aminosalicylic acid (5ASA) as a clinical result of
Immunopure. Patients were randomized to either the
Immunopure therapy (steroid-free) group (12 patients) or
the conventional drug therapy withdrawal program
(prednisolone tapering) group (10 patients). The primary
endpoint was the steroid-free clinical remission rate at
Week 12. Clinical response was assessed based on the dis-
ease activity index (DAI). Both groups exhibited a signifi-
cant improvement in disease status at Week 7 post-end of
treatment. After the end of treatment, the steroid group
appeared to be headed toward disease reactivation fol-
lowing steroid withdrawal, whereas the improvement
appeared to be sustained in the Immunopure therapy
group. This suggests that apheresis may eliminate the
need for steroids and allow patients to achieve sustained
remission.
2.3 | Clinical trial in Japan
In Japan, a clinical trial involving 70 patients with refrac-
tory moderate UC at seven sites (Sapporo Hokuyu Hospital,
Iwate Medical University, Saitama Medical Center, Kana-
zawa University Hospital, Japan Community Health care
Organization Chukyo Hospital, Osaka Medical College Hos-
pital, Shin-Koga Hospital) was planned from February 2015
to October 2019, but prematurely discontinued due to diffi-
culty in patient recruitment. Immunopure was used twice
weekly for 10 consecutive times. The primary endpoint was
the clinical remission rate at Week 7. Clinical response was
assessed based on Rachimilewitz CAI.
3 | RESULTS AND DISCUSSION
3.1 | Clinical trial in Japan
Table 3 summarizes the results from 13 patients with eva-
luable data. As a result from 11 patients who is efficacy
analysis target population, that remission rate was
achieved in 63.6% of patients (7/11). The effectiveness of
Immnopure was also evaluated by comparing pooled
TABLE 2 Adsorption character of Immunopure in accordance with the result of previous clinical trials
Platelets Leukocytes Lymphocytes Monocytes Granulocytes
Mean ± standard deviation
(10 patients in a European clinical triala)
41.0 ± 22.3 29.6 ± 14.8 3.9 ± 7.0 42.6 ± 25.2 34.1 ± 17.8
Mean ± standard deviation
(10 patients in a Japanese clinical trial)
49.3 ± 17.2 29.6 ± 16.4 2.8 ± 6.9 49.6 ± 18.7 35.6 ± 20.0
aNikkiso internal data, not published.
FIGURE 1 The novel apheresis device Immunopure [Color
figure can be viewed at wileyonlinelibrary.com]
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results from this study and previous European clinical tri-
als with the abovementioned data from publications con-
cerning treatment with the CA and PET columns.
Subgroup analyses of remission rates showed that remis-
sion was achieved in 70.4% of patients receiving
Immunopure therapy vs. 61.8% to 67.3% of patients using
other columns in the moderate disease population and in
69.6% vs. 51.7% to 74.1%, respectively, in the refractory
disease population [2,5,6,8–14]. This demonstrates that
Immunopure is comparable to existing products in terms
of clinical effectiveness in refractory moderate disease.
Immunopure, which is covered by health insurance
for use in patients with moderate UC, was launched
around the same time that the marketing of the PET col-
umn was unfortunately discontinued. This is a welcome
development, providing healthcare professionals with
multiple treatment options in clinical practice. Although
only a limited number of patients were treated in the Jap-
anese clinical trial, the Immunopure apheresis device,
which is supported by overseas post-marketing experi-
ence, became clinically available in 2020.
Drug therapy is evolving, but apheresis is well known
to be safer than steroids. Immunopure thus offers a
promising treatment option.
4 | CONCLUSION
Immunopure is comparable to other products in clinical
effectiveness and indicated for the treatment of patients
with refractory moderate ulcerative colitis, making it
highly useful in clinical practice.
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